报告期内，亚盛医药的商业化造血能力逐步增强；耐立克的商业化快速推进，实现销售收入人民币1.13亿元，较去年下半年环比增长120%，较去年上半年同比增长5%。Asia Pharmaceutical-B (06855) rose more than 4% after the performance announcement, reaching a 4.13% increase with a price of HKD 29 and a turnover of HKD 9.569 million.
According to the Smart Finance App, Asia Pharmaceutical-B (06855) rose more than 4% after the performance announcement, reaching a 4.13% increase with a price of HKD 29 and a turnover of HKD 9.569 million.
On the news front, Asia Pharmaceutical-B released its mid-year performance for 2024. The company achieved record high total revenue in the first half of the year and achieved profitability for the first time. During the reporting period, Asia Pharmaceutical achieved record high revenue of RMB 0.824 billion, a year-on-year increase of 477%, mainly from product sales and external cooperation authorization income. The company achieved a turnaround from losses to profits for the first time, with a net profit of RMB 0.163 billion. The company's cash flow has continued to improve and remains robust.
During the reporting period, Asia Pharmaceutical's commercial hematopoietic capacity gradually strengthened. The commercialization of Naliteke has advanced rapidly, achieving sales revenue of RMB 0.113 billion, a 120% increase compared to the second half of last year and a 5% increase compared to the first half of last year.
